A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

NCT02251288 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

62

Enrollment

NIH

Sponsor class

Conditions

Avian Influenza
Immunisation

Interventions

BIOLOGICAL: Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca
BIOLOGICAL: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
DRUG: MF59 adjuvant

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)